243 related articles for article (PubMed ID: 15047808)
1. EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.
Gordadze AV; Onunwor CW; Peng R; Poston D; Kremmer E; Ling PD
J Virol; 2004 Apr; 78(8):3919-29. PubMed ID: 15047808
[TBL] [Abstract][Full Text] [Related]
2. The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance.
Gordadze AV; Poston D; Ling PD
J Virol; 2002 Jul; 76(14):7349-55. PubMed ID: 12072534
[TBL] [Abstract][Full Text] [Related]
3. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
Harada S; Yalamanchili R; Kieff E
J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
[TBL] [Abstract][Full Text] [Related]
4. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
Fuentes-Pananá EM; Ling PD
J Virol; 1998 Jan; 72(1):693-700. PubMed ID: 9420275
[TBL] [Abstract][Full Text] [Related]
6. Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts EBNA2 activity.
Ponnusamy R; Khatri R; Correia PB; Wood CD; Mancini EJ; Farrell PJ; West MJ
PLoS Pathog; 2019 Jul; 15(7):e1007458. PubMed ID: 31283782
[TBL] [Abstract][Full Text] [Related]
7. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes.
Zimber-Strobl U; Strobl LJ
Semin Cancer Biol; 2001 Dec; 11(6):423-34. PubMed ID: 11669604
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.
Fuentes-Pananá EM; Peng R; Brewer G; Tan J; Ling PD
J Virol; 2000 Sep; 74(17):8166-75. PubMed ID: 10933728
[TBL] [Abstract][Full Text] [Related]
9. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.
Peng R; Moses SC; Tan J; Kremmer E; Ling PD
J Virol; 2005 Apr; 79(7):4492-505. PubMed ID: 15767449
[TBL] [Abstract][Full Text] [Related]
10. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus.
Gordadze AV; Peng R; Tan J; Liu G; Sutton R; Kempkes B; Bornkamm GW; Ling PD
J Virol; 2001 Jul; 75(13):5899-912. PubMed ID: 11390591
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.
Abbot SD; Rowe M; Cadwallader K; Ricksten A; Gordon J; Wang F; Rymo L; Rickinson AB
J Virol; 1990 May; 64(5):2126-34. PubMed ID: 2157875
[TBL] [Abstract][Full Text] [Related]
12. BS69/ZMYND11 C-Terminal Domains Bind and Inhibit EBNA2.
Harter MR; Liu CD; Shen CL; Gonzalez-Hurtado E; Zhang ZM; Xu M; Martinez E; Peng CW; Song J
PLoS Pathog; 2016 Feb; 12(2):e1005414. PubMed ID: 26845565
[TBL] [Abstract][Full Text] [Related]
13. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter.
Zimber-Strobl U; Kremmer E; Grässer F; Marschall G; Laux G; Bornkamm GW
EMBO J; 1993 Jan; 12(1):167-75. PubMed ID: 8381349
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
[TBL] [Abstract][Full Text] [Related]
15. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide.
Farrell CJ; Lee JM; Shin EC; Cebrat M; Cole PA; Hayward SD
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4625-30. PubMed ID: 15070768
[TBL] [Abstract][Full Text] [Related]
17. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
Yoo L; Speck SH
J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism analysis of Epstein-Barr virus isolates from patients with cutaneous natural killer/T-cell lymphoproliferative disorders: A possible relation to the endemic occurrence of these diseases in Japan.
Xu ZG; Iwatsuki K; Ohtsuka M; Oyama N; Matsui T; Kaneko F
J Med Virol; 2000 Oct; 62(2):239-46. PubMed ID: 11002254
[TBL] [Abstract][Full Text] [Related]
19. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
Sjöblom A; Nerstedt A; Jansson A; Rymo L
J Gen Virol; 1995 Nov; 76 ( Pt 11)():2669-78. PubMed ID: 7595374
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
J Virol; 2018 May; 92(9):. PubMed ID: 29467311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
